Effects of Glucose-Lowering Medications on Intrapancreatic Fat Deposition: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Abstract
BACKGROUND: The pancreas is a key metabolic organ, and excessive intrapancreatic fat deposition (IPFD) has been implicated in the pathogenesis of Type 2 diabetes. Although IPFD is believed to be reversible, it remains unclear whether glucose-lowering medications can reduce it. This study aimed to perform a field-wide systematic review of randomized controlled trials (RCTs) investigating the effects of such medications on IPFD.
METHODS: Three electronic databases-MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials-were searched. RCTs comparing the effects of pharmacological interventions with standard care or placebo on IPFD were meta-analyzed using a random-effects model. The mean difference in IPFD, with its corresponding 95% confidence interval, served as the primary effect estimate.
RESULTS: Eight RCTs met the eligibility criteria, five of which were placebo-controlled. In the overall analysis, glucose-lowering medications were associated with a significant reduction in IPFD (mean difference = -1.5; 95% CI: -1.8, -1.1; p < 0.001). Constraining the analysis to placebo-controlled RCTs yielded a larger effect size (mean difference = -1.8; 95% CI: -3.1, -0.5; p = 0.01). Among the medication classes meta-analyzed, significant reductions in IPFD were observed with GLP-1 receptor agonists (mean difference = -1.6; 95% CI: -2.5, -0.7; p = 0.01) and SGLT-2 inhibitors (mean difference = -1.4; 95% CI: -1.6, -1.1; p = 0.002).
CONCLUSION: Glucose-lowering…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
- Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials
- Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
- Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta‐analysis, and network meta‐analysis of randomized trials with 94,283 participants
- Screen time increases overweight and obesity risk among adolescents: a systematic review and dose-response meta-analysis
- Exposure to WHO AWaRe antibiotics and isolation of multi-drug resistant bacteria: a systematic review and meta-analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.